Importantly, therapeutic strategies targeting CD4+ T cell infiltration or MHC class II expression have shown efficacy in mitigating nigrostriatal dopaminergic neuronal damage in α-synuclein overexpression models of Parkinson’s disease [16]. This evidence concerns the gene CD4 and Parkinson disease.